Peer-influenced content. Sources you trust. No registration required. This is HCN.

Essential Medical Reading

Your Weekly Roundup of the Most-Read News and Clinical References from Your Peers

Journal of Clinical Oncology

COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination with Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer (NSCLC)

Oncology, Medical May 25th 2022

MashupMD

Omicron’s Surprising Anatomy Explains Why It Is Wildly Contagious

Allergy & Immunology May 24th 2022

Medical Professionals Reference (MPR)

Gabapentin-Involved Overdose Deaths Increased Between 2019 and 2020

Clinical Pharmacology May 24th 2022

Medical Professionals Reference (MPR)

FDA Approves First-in-Class Treatment for Type 2 Diabetes

Endocrinology, Diabetes, Metabolism May 24th 2022

ACP Internist

IDSA Offers Guidance on Managing Drug Interactions with Nirmatrelvir/Ritonavir

Allergy & Immunology May 24th 2022

Journal of Clinical Oncology

Chicago’s Hidden Gem Restaurants for ASCO

Hematology/Oncology May 18th 2022

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form